1. Home
  2. INLX vs NXTC Comparison

INLX vs NXTC Comparison

Compare INLX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

N/A

Current Price

$4.17

Market Cap

21.6M

Sector

Technology

ML Signal

N/A

Logo NextCure Inc.

NXTC

NextCure Inc.

SELL

Current Price

$6.48

Market Cap

24.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
INLX
NXTC
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
24.8M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
INLX
NXTC
Price
$4.17
$6.48
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $20.00
AVG Volume (30 Days)
26.2K
★ 62.7K
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
$11,336.00
★ $22,378,000.00
Revenue This Year
$14.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.01
$1.55
52 Week High
$9.45
$15.74

Technical Indicators

Market Signals
Indicator
INLX
NXTC
Relative Strength Index (RSI) 39.53 55.29
Support Level $4.12 $4.20
Resistance Level $5.80 $8.68
Average True Range (ATR) 0.61 0.84
MACD -0.05 0.04
Stochastic Oscillator 6.20 61.05

Price Performance

Historical Comparison
INLX
NXTC

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: